Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

biotech_sellout May. 15 at 6:49 PM

$ESPR

0 · Reply

biotech_sellout May. 15 at 6:40 PM

$ESPR And I expect the desperate pumptard to be wrong yet again. In fact, he's never been right.

0 · Reply

monster6969 May. 15 at 6:19 PM

$ESPR Esperion recorded $2.1 million in collaboration revenue from its collaboration with Otsuka Pharmaceutical in Q1 2026. This income consisted of: Royalties on Japanese sales of Nexletol as well as sales of bulk tablets to Otsuka.

0 · Reply

Gregg617 May. 15 at 5:52 PM

$ESPR

0 · Reply

Bull_Donald May. 15 at 5:32 PM

$ESPR you are showing early symptoms. 😀 be careful, it may consume you.

1 · Reply

DP000 May. 15 at 5:10 PM

$ESPR My highly scientific guesstimate says sometime within the first 2 weeks of June. Sources include vibes, caffeine, and absolutely zero insider information 😎…Happy Friday to you all, longs!

2 · Reply

Gregg617 May. 15 at 5:01 PM

$ESPR

0 · Reply

WinnersParadise May. 15 at 4:31 PM

$BABA $QBTS $ESPR $CRM ::

0 · Reply

NEXLIZET_REALWORLD_STUDY May. 15 at 4:22 PM

$ESPR I exoect a new offer will be presented in June July. $$$$$

0 · Reply

ablor May. 15 at 4:09 PM

$ESPR At this point, we should probably start writing the boards of BPs. As useless as that will be, it is likely more effective than writing ESPR's board.

0 · Reply

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 13, 2026, 8:00 AM EDT - 2 days ago

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

2026-05-04T19:10:14.000Z - 10 days ago

Esperion downgraded to Hold from Buy at Needham

2026-05-01T19:26:03.000Z - 13 days ago

Esperion downgraded to Hold from Buy at Jefferies

2026-05-01T18:06:50.000Z - 14 days ago

Esperion downgraded to Neutral from Overweight at Piper Sandler

2026-05-01T15:12:52.000Z - 14 days ago

Esperion downgraded to Neutral from Buy at H.C. Wainwright

2026-05-01T12:46:24.000Z - 14 days ago

Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald

May 1, 2026, 7:37 AM EDT - 14 days ago

Archimed to take Esperion Therapeutics private in $1.1 billion deal

2026-05-01T11:17:53.000Z - 14 days ago

Esperion to be acquired by Archimed for $3.16 per share, one CVR

May 1, 2026, 7:00 AM EDT - 14 days ago

Esperion to be Acquired by ARCHIMED

Apr 23, 2026, 8:00 AM EDT - 22 days ago

Esperion to Report First Quarter 2026 Financial Results on May 7

Apr 13, 2026, 9:30 AM EDT - 4 weeks ago

Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-02T20:16:16.000Z - 6 weeks ago

Esperion, Athyrium Capital enter $50M royalty financing agreement

Apr 2, 2026, 4:05 PM EDT - 6 weeks ago

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Apr 2, 2026, 4:00 PM EDT - 6 weeks ago

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

2026-03-30T13:21:46.000Z - 6 weeks ago

Esperion showcases new data from CLEAR Outcomes trial

2026-03-16T10:51:45.000Z - 2 months ago

Esperion says bempedoic acid receives recommendations in ACC/AHA Guideline

Mar 16, 2026, 6:30 AM EDT - 2 months ago

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

2026-03-13T09:36:20.000Z - 2 months ago

Esperion price target raised to $5 from $4 at Citizens

Mar 11, 2026, 8:25 AM EDT - 2 months ago

Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026

2026-03-10T12:06:41.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 10, 2026

AVAV BNTX FNV GRPN KSS NIO ORCL

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Esperion Therapeutics Earnings Call Transcript: Q4 2025

2026-03-10T10:06:52.000Z - 2 months ago

Esperion reports Q4 EPS 22c, consensus 28c

2026-03-10T10:06:13.000Z - 2 months ago

Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025

Mar 10, 2026, 6:00 AM EDT - 2 months ago

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 3, 2026, 8:00 AM EST - 2 months ago

Esperion Therapeutics Transcript: M&A announcement

2026-03-03T11:05:38.000Z - 2 months ago

Esperion signs definitive acquisition of Corstasis Therapeutics

Mar 3, 2026, 6:00 AM EST - 2 months ago

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Feb 18, 2026, 8:00 AM EST - 3 months ago

Esperion to Participate in The 2026 Citizens Life Sciences Conference

2026-02-17T13:16:28.000Z - 3 months ago

Esperion reaches settlement agreement with Alkem

Feb 17, 2026, 8:00 AM EST - 3 months ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Jan 14, 2026, 5:15 PM EST - 4 months ago

Esperion Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T00:25:16.000Z - 4 months ago

Esperion reports preliminary FY25 revenue $400M-$408M, consensus $393.11M

Jan 11, 2026, 6:00 PM EST - 4 months ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

2025-12-19T13:16:23.000Z - 5 months ago

Esperion’s bempedoic acid receives recommendation in 2025 ACC statement

Dec 3, 2025, 3:30 PM EST - 5 months ago

Esperion Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 7:00 AM EST - 6 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 18, 2025, 3:00 AM EST - 6 months ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 2:00 PM EST - 6 months ago

Esperion Therapeutics Transcript: KOL Event

Nov 6, 2025, 8:00 AM EST - 6 months ago

Esperion Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 6 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 7, 2025, 9:29 PM EDT - 7 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 7 months ago

Esperion Announces Proposed Public Offering of Common Stock

Oct 3, 2025, 8:00 AM EDT - 8 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Sep 19, 2025, 8:00 AM EDT - 8 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 8, 2025, 2:00 PM EDT - 8 months ago

Esperion Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:45 AM EDT - 9 months ago

Esperion Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 8:00 AM EDT - 9 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Esperion Therapeutics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 10 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 11 months ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 9, 2025, 10:40 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 1:25 PM EDT - 1 year ago

Esperion Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 10:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:30 PM EDT - 1 year ago

Esperion Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 6:30 AM EDT - 1 year ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Esperion Therapeutics Transcript: Status Update

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 7, 2025, 8:45 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q4 2024

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Jan 22, 2025, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: KOL Event

Jan 15, 2025, 6:45 PM EST - 1 year ago

Esperion Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 5, 2024, 12:30 PM EST - 1 year ago

Esperion Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 11:30 AM EST - 1 year ago

Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 1 year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 19, 2024, 10:55 AM EDT - 1 year ago

Esperion Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2024, 10:55 AM EDT - 1 year ago

Esperion Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Esperion Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jul 16, 2024, 8:00 AM EDT - 1 year ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Jun 28, 2024, 7:00 AM EDT - 2 years ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

biotech_sellout May. 15 at 6:49 PM

$ESPR

0 · Reply

biotech_sellout May. 15 at 6:40 PM

$ESPR And I expect the desperate pumptard to be wrong yet again. In fact, he's never been right.

0 · Reply

monster6969 May. 15 at 6:19 PM

0 · Reply

Gregg617 May. 15 at 5:52 PM

$ESPR

0 · Reply

Bull_Donald May. 15 at 5:32 PM

$ESPR you are showing early symptoms. 😀 be careful, it may consume you.

1 · Reply

DP000 May. 15 at 5:10 PM

$ESPR My highly scientific guesstimate says sometime within the first 2 weeks of June. Sources include vibes, caffeine, and absolutely zero insider information 😎…Happy Friday to you all, longs!

2 · Reply

Gregg617 May. 15 at 5:01 PM

$ESPR

0 · Reply

WinnersParadise May. 15 at 4:31 PM

$BABA $QBTS $ESPR $CRM ::

0 · Reply

NEXLIZET_REALWORLD_STUDY May. 15 at 4:22 PM

$ESPR I exoect a new offer will be presented in June July. $$$$$

0 · Reply

ablor May. 15 at 4:09 PM

$ESPR At this point, we should probably start writing the boards of BPs. As useless as that will be, it is likely more effective than writing ESPR's board.

0 · Reply

ablor May. 15 at 4:07 PM

$ESPR Just for fun, Endpoints news had an article today about non-traditional acquirers ramping up activity in biotech M&A. There was an example (not the best one for non-traditional acquirers) acquisition of KalVista recently for their $1.9B. This was for their hereditary angioedema drug. AI says the US market TAM for this is $1.25B, expected to grow to ~2.5B over the next several years. They paid nearly 2B for this! Imagine what BA is worth. US market TAM for lipid-lowering/primary prevention, etc is several 10s of billions (approaching a hundred billion). 5% penetration with statin intolerance, MACE reduction, etc makes this more valuable than KalVista, not even counting ACLYi pipeline. Just another way to put into perspective what a lousy scam this deal is.

0 · Reply

biokvint May. 15 at 2:10 PM

$ESPR At least it doesn’t move with the market🤣😂

0 · Reply

maxhappy May. 15 at 1:57 PM

$ESPR Here they are for those who care: Scripts were mixed, according to the latest weekly data I have from Symphony. Nexlizet down 4.7% but Nexletol up 2.2% to a record. This compares with competitive drugs (Atorvastatin, Repatha, and Ezetimibe) that were also mixed and + or - less than 1%.

2 · Reply

afindling May. 15 at 1:04 PM

$ESPR scripts anyone?

0 · Reply

Enjoyycall May. 15 at 12:28 PM

$ESPR They gone…vapor… swoosh. Post your gain porn now ladies and gentlemen…Or loss, but I guess you can’t “try” now lol

1 · Reply

biotech_sellout May. 15 at 12:09 PM

$ESPR HAPPY BUYOUT ANNIVERSARY! IT WAS 2 WEEKS AGO THAT OUR FEARED AND STRATEGIC CEO SHELDON "KICKASS" KOENIG AND ESPERION'S BOD AGREED TO A WONDERFUL BUYOUT BY A FRENCH HEALTH INVESTMENT FIRM THAT MADE ALL OF US FILTHY RICH! JUST AS WE ALL HOPED HE WOULD.

0 · Reply

Hawaiianinvesta May. 15 at 2:25 AM

$ESPR our only hope is that tutes dont back this deal, as they are getting low balled and shafted too Id rather take the breakup fee of $70M then this deal go through at 3.16 and worthless cvrs

3 · Reply

Enjoyycall May. 15 at 2:06 AM

$ESPR

2 · Reply

YoloAlfred May. 15 at 1:06 AM

$ESPR Do not say i didn't tell you $VBIO.....For the medical nerds look up ENTOLIMOD & ENTOLASTA....Go to ClinicalTrials.gov. Company is pursuing US STRATEGIC STOCKPILE CONTRACT first for US/ UKRAINE/ NATO...With that cash ALL OUR WILDEST DREAMS WILL COME TRUE. ( famous quote/ great movie should have won an Emmy🤓)

0 · Reply

YoloAlfred May. 15 at 12:40 AM

$VBIO Valion is not f@#$ING around.....wish i had this management with my old position $ESPR

0 · Reply

NEWBIGTECH May. 14 at 10:30 PM

$ESPR here's an idea . Let's all stop selling $ESPR So cheap. Set sales at $3.16 + .50 cents 3.66 or higher.

2 · Reply

BBRC May. 14 at 9:53 PM

$ESPR I would suspect most of the trading is being done by arbitrafe funds. But not all the trading. I bought more shares today. Maybe we get a topping bid and maybe not. Maybe I take my shares to appraisal. Maybe I just collect a few pennies and the CVR rights at closing. Lots of time left on this trade.

3 · Reply

Market Cap	803.19M
Revenue (ttm)	403.14M
Net Income (ttm)	-22.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	68.04
Profit Margin	-5.63%
Debt to Equity Ratio	-0.50

Volume	5,421,867
Avg Vol	12,490,112
Day's Range	N/A - N/A
Shares Out	257.43M
Stochastic %K	25%
Beta	0.91
Analysts	Hold
Price Target	$2.91